Home › U.S. judge rejects Amgen bid to block 'biosimilar' Neupogen
 

Keywords :   


U.S. judge rejects Amgen bid to block 'biosimilar' Neupogen

2015-03-19 22:40:00| Biotech - Topix.net

A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients. The drug, Zarxio, contains the same active ingredient as Amgen's $1.2 billion-a-year Neupogen, and once launched, would become the first biosimilar in the United States.

Tags: block bid judge rejects

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
08.07Tropical Storm Beryl Public Advisory Number 37A
08.07Summary for Tropical Storm Beryl (AT2/AL022024)
08.07WTO chief warns against global trade breakdown
08.07Eastern North Pacific Tropical Weather Outlook
08.07Atlantic Tropical Weather Outlook
08.07Tropical Storm Beryl Potential Storm Surge Flooding Map
07.07Tropical Storm Beryl Probabilistic Storm Surge Graphics
07.07Tropical Storm Beryl Graphics
More »